These agents, known for their dual impact on both immune modulation and metabolic improvement, offer a unique therapeutic potential in managing immune-mediated inflammatory diseases ( 3.2 GLP-1RAs in psoriatic arthritis The therapeutic landscape of PsA is currently dominated by targeted agents that inhibit key inflammatory pathways, including TNF inhibitors (e.g., adalimumab, etanercept), IL17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and Janus kinase (JAK) inhibitors such as upadacitinib and tofacitinib ( Several studies have reported an inverse relationship between BMI and therapeutic efficacy, indicating that obesity may attenuate clinical responses to biologic disease modifying anti-rheumatic drugs (bDMARDs)
10.1016/s0006-8993(97)00008-5 Brain Res
Pantoliano, M
Am I still shocked that I did it
Ideal para: Personas con manchas o tono desigual
Its Phase 2/3 LIFT-AD Alzheimer's trial failed its primary endpoint (announced September 3, 2024